Abstract | BACKGROUND AND OBJECTIVES: METHODS AND RESULTS: Between 1 September 2019 and 4 December 2020, 367 patients from the CHIEF cohort received at least one locoregional (52.8%) chemoembolization or radioembolization or systemic treatment (88.3%) and were selected for ELITor. Most patients had a Barcelona Clinic Liver Cancer (BCLC) C (93.2%) hepatocellular carcinoma stage and were affected by cirrhosis (67.7%). Alcohol was confirmed as the main etiology both as a single etiology (29.1%) and in association with other risk factors (26.9%), mainly metabolic disorders (16.2%). Tyrosine-kinase inhibitors, mainly sorafenib, were the most administered systemic treatments in first line. Patients who received at least one combination of atezolizumab and bevacizumab during the study period ( N = 53) had a better performance status and less portal hypertension frequency than the overall population and more hepatitis B virus infection and fewer metabolic disorders as single etiology. Overall, the global health score before treatment (62.3 ± 21.9) was in line with that of reference cancer patients and worsened in 51.9% of the cases after first-line palliative-intent treatment. CONCLUSION:
|
Authors | Eric Nguyen-Khac, Pierre Nahon, Olivier Ganry, Hajer Ben Khadhra, Philippe Merle, Giuliana Amaddeo, Nathalie Ganne-Carrie, Christine Silvain, Jean-Marie Peron, Philippe Mathurin, Rodolphe Anty, Thomas Uguen, Thomas Decaens, Ghassan Riachi, Mohamed Bouattour, Aurore Baron, Jean-Pierre Bronowicki, Georges-Philippe Pageaux, Olivier Rosmorduc, Gérard Ducournau, Mélina Gilberg, Alexandre Tanang, Julien Dupin, Anika Gilbert-Marceau, Jean-Frédéric Blanc, French CHIEF cohort group |
Journal | European journal of gastroenterology & hepatology
(Eur J Gastroenterol Hepatol)
Vol. 35
Issue 10
Pg. 1168-1177
(10 01 2023)
ISSN: 1473-5687 [Electronic] England |
PMID | 37577805
(Publication Type: Journal Article)
|
Copyright | Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved. |
Chemical References |
|
Topics |
- Humans
- Carcinoma, Hepatocellular
(therapy, drug therapy)
- Liver Neoplasms
(therapy, drug therapy)
- Bevacizumab
(adverse effects)
- Retrospective Studies
- Quality of Life
- Prospective Studies
- Chemoembolization, Therapeutic
(adverse effects, methods)
- Immunotherapy
(adverse effects)
|